

Q2 2015 [VentureDeal](#) Quarterly Venture Capital Report Biotechnology - Medical Devices - Pharmaceuticals

Life Science companies secured \$3.7 billion in venture capital financing during Q2 2015, representing an increase of 14% versus the previous quarter. The funding was allocated between 219 companies, an 8% decrease versus the previous quarter.


Biotechnology

Biotechnology funding was down from the previous quarter, decreasing by 6% during the quarter. The number of companies funded also decreased, by 4% versus the previous quarter.

San Francisco-based [Denali Therapeutics](#) raised \$217 million in venture equity capital to continue development of medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. Investors included [Fidelity BioSciences](#), [ARCH Venture Partners](#), [Flagship Ventures](#) and the [Alaska Permanent Fund](#).

Gene editing technology company [Caribou Biosciences](#) raised \$11 million from investors including strategic investor [Novartis BioVenture Fund](#), according to a company statement. Caribou is developing what it calls an “advanced genome editing platform” using Cas9, a protein derived from the CRISPR prokaryotic immune system.

Biotechnology Funding - 2nd Quarter 2015




Pharmaceuticals

Pharmaceutical fundings increased to \$900 million, representing a 35% increase in amounts funded but a 31% decrease in the number of companies funded - 34 versus the previous quarter.

Boston, Massachusetts-based [Intarcia Therapeutics](#) raised \$225 million in venture debt capital from undisclosed investors. The company said it plans to use the funds to accelerate the initiation of additional head-to-head comparative and switch studies of its ITCA 650 candidate versus leading oral and injectable type II diabetes therapies. Intarcia is backed by a large syndicate of institutional venture capital, private equity and late stage investors.

Quebec-based [Clementia Pharmaceuticals](#) raised \$60 million in equity capital from a large syndicate of venture capital and corporate investors led by [New Enterprise Associates](#). The company said that the financing will allow it to continue focusing on its priority of developing palovarotene as a potential treatment option for patients with Fibrodysplasia Ossificans Progressiva (FOP).

Pharmaceuticals Funding - 2nd Quarter 2015



Medical Devices

Venture capital funding for Medical Device companies increased by 46% in total amounts funded, to \$1.1 billion. The number of companies funded remained exactly the same at 91.

The largest funding event during the quarter was \$197 million in venture equity for Hayward, California-based [Moximed](#). The company is developing a new device called the KineSpring System that it believes reduces the load on the knee, reducing pain that osteoarthritis sufferers experience. The transaction was found via an SEC regulatory filing, and the company did not say how the funding proceeds would be used, nor who the investors were.

Medical Devices Funding - 2nd Quarter 2015




Table 1
Venture Capital Funding - 2nd Quarter 2015

| Industry | Total Disclosed Funding | % Change Vs. Prior Quarter | Number of Companies Funded | % Change vs. Prior Quarter |
|-----------------|-------------------------|----------------------------|----------------------------|----------------------------|
| Biotechnology | \$1.7 billion | - 6 % | 94 | - 4 % |
| Pharmaceuticals | \$900 million | + 35 % | 34 | - 31 % |
| Medical Devices | \$1.1 billion | + 46 % | 91 | -- |
| Total | \$3.7 billion | + 14 % | 219 | - 8 % |

This material has been prepared and issued by VentureDeal. The information contained herein is based on current information that VentureDeal considers reliable, but we make no representation that it is accurate in the future or complete, and it should not be relied upon as such. It is provided with the understanding that VentureDeal is not acting in a fiduciary capacity.